Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
Quote | Aclaris Therapeutics Inc. (NASDAQ:ACRS)
Last: | $2.33 |
---|---|
Change Percent: | 0.0% |
Open: | $2.18 |
Close: | $2.33 |
High: | $2.35 |
Low: | $2.17 |
Volume: | 473,669 |
Last Trade Date Time: | 02/14/2025 03:00:00 am |
News | Aclaris Therapeutics Inc. (NASDAQ:ACRS)
- Data Generated to Date Support Potential for Aclaris’ ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product can...
2025-02-11 07:09:18 ET Summary Aclaris' stock has dropped nearly 70% since September 2023, reflecting its history of failures and dissipations. The company’s lead asset, ATI-045, shows promising phase 2a results in atopic dermatitis, but skepticism remains due to past failu...
Message Board Posts | Aclaris Therapeutics Inc. (NASDAQ:ACRS)
Subject | By | Source | When |
---|---|---|---|
I was short premarket 20.30 then quickly covered | alchemytrader | investorshub | 01/20/2021 10:19:02 PM |
ACRS offering more than 5m shares at $17.50/per share | SteevoTrader | investorshub | 01/20/2021 2:01:58 PM |
The way she kept grinding back to 19s | alchemytrader | investorshub | 01/20/2021 4:50:21 AM |
Are we seeing a dump tomorrow? | SteevoTrader | investorshub | 01/20/2021 1:57:36 AM |
Oh really? hit 19.95 today... | alchemytrader | investorshub | 01/20/2021 12:55:29 AM |
News, Short Squeeze, Breakout and More Instantly...
Aclaris Therapeutics Inc. Company Name:
ACRS Stock Symbol:
NASDAQ Market:
Aclaris Therapeutics Inc. Website:
- Data Generated to Date Support Potential for Aclaris’ ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product can...
WAYNE, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fires...
2024-11-19 16:12:40 ET A %Healthcare company based out of Pennsylvania caused quite the stir on Tuesday after the company announced that it had entered into an exclusive license agreement with Biosion Inc. for worldwide rights (excluding Greater China) to BSI-045B and BSI-502, a preclin...